Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.

NCT01212107 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01212107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01212107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
February 28, 2015
Enrollment
94 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer